EuBiologics

Oral cholera vaccine made in the company's own facilities and supplied to UNICEF; the company produces and supplies three oral cholera vaccines: Euvichol (glass vial), Euvichol-Plus and Euvichol-S.

In-house typhoid conjugate vaccine that received WHO prequalification in August 2026; a multidose formulation with five doses in one 2.5 mL vial.

Shingles vaccine candidate; in October 2026 the company disclosed results of a Korean phase 1 trial in 72 healthy adults aged 50 to 69 and applied for approval of a Korean phase 2 trial plan.

Pentavalent meningococcal conjugate vaccine candidate; the company says it is in the development and approval stage and is pursuing WHO prequalification.

Second plant, a vaccine production site in Dongsan-myeon, Chuncheon, Gangwon; the board approved a 111.5 billion won investment to build a third plant on the same site by 2028 with finished-vial and drug-substance lines.

The board approved a 111.5 billion won investment in a third plant at the Chuncheon second-plant site, planned by 2028 with finished-vial lines for typhoid and meningococcal vaccines and drug-substance lines for RSV, shingles and Alzheimer's vaccines.

The typhoid conjugate vaccine EuTYPH-C Inj. received WHO prequalification, making it eligible for international public procurement bids; the company now has four WHO-prequalified products, including three cholera vaccines.

Disclosed Korean phase 1 results for the shingles vaccine candidate EuHZV, reporting no serious adverse events in the primary study period, and applied for approval of a phase 2 trial in 150 adults aged 50 or older.

Signed a 10.5 billion won contract with UNICEF (Mozambique) to supply the oral cholera vaccine Euvichol-S through January 31, 2027, from its own production facilities.